Immediate Impact

1 from Science/Nature 56 standout
Sub-graph 1 of 19

Citing Papers

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Pancreatic cancer
2025 Standout
1 intermediate paper

Works of Simon Tian being referenced

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
2019
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB)
2019
and 3 more

Author Peers

Author Last Decade Papers Cites
Simon Tian 944 87 89 90 30 998
Stefanie J. Millar 793 61 47 45 29 881
Donatello Salvatore 733 24 44 58 56 851
Edward F. McKone 1009 44 84 33 40 1.3k
Sheila G. McKenzie 872 41 46 51 14 1.1k
William T. Harris 959 65 27 77 41 1.2k
Nico Derichs 1213 36 21 56 32 1.4k
Kathleen Naughton 796 47 16 64 17 980
Vincent Gulmans 695 30 16 93 27 909
Vicky A. LeGrys 1098 17 16 54 30 1.4k
Y. Yahav 726 41 10 90 32 980

All Works

Loading papers...

Rankless by CCL
2026